UBS Group AG Registered Ordinary Shares (UBS)

47.61
+0.00 (0.00%)
NYSE · Last Trade: Nov 17th, 9:18 AM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Gilead Sciences Bets on HIV Prevention Growth Despite $1.5 Billion Biktarvy Headwindmarketbeat.com
Gilead Sciences (NASDAQ:GILD) expects its expanding HIV prevention portfolio and a potential new cell therapy for multiple myeloma to support growth, even as a negotiated price change for its HIV treatment Biktarvy creates an anticipated $1.5 billion headwind in 2028, Chief Financial Officer Andy Di
Via MarketBeat · November 17, 2026
Cytokinetics Touts MYQORZO Launch Momentum, Plans New FDA Filingmarketbeat.com
Cytokinetics (NASDAQ:CYTK) executives said the company is seeing momentum in the launch of heart drug MYQORZO and is preparing to seek U.S. approval for its use in a second form of hypertrophic cardiomyopathy. Speaking at the UBS Biopharma Conference, President and CEO Robert Blum also announced th
Via MarketBeat · November 17, 2026
Ultragenyx Pharmaceutical Targets 2027 Profitability After Deep Cuts and Gene Therapy Launchesmarketbeat.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) expects to reach profitability in 2027 as it cuts spending, expands sales of existing rare-disease treatments and launches two gene therapies, executives said at the UBS Global Biopharma Conference. CEO Emil Kakkis said the company is heading toward $1 billio
Via MarketBeat · November 17, 2026
United Therapeutics Prepares for TYVASO Expansion After $833 Million Quartermarketbeat.com
United Therapeutics (NASDAQ:UTHR) is preparing for a potential expansion of its TYVASO franchise into idiopathic pulmonary fibrosis, while its executives pointed to strong third-quarter sales and a pipeline of regulatory and clinical milestones at the UBS London Healthcare Conference. The company r
Via MarketBeat · November 16, 2026
Ionis Pharmaceuticals Sticks to $3 Billion TRYNGOLZA Sales Goal Despite Slow Startmarketbeat.com
Ionis Pharmaceuticals (NASDAQ:IONS) remains confident that its triglyceride-lowering drug TRYNGOLZA can generate more than $3 billion in peak annual U.S. sales, even as its launch has started more slowly than expected, CEO Brett Monia said at the UBS Global Biopharma Conference. Monia said physicia
Via MarketBeat · November 16, 2026
Nvidia Stock Might Have a Bigger Problem Than Replacing Jensen Huang. What Happens If It Loses 15% of Its Revenue?fool.com
Analysts now warn that scrutiny in China could put up to 15% of Nvidia's revenue at risk.
Via The Motley Fool · November 16, 2026
Axsome Therapeutics Sees AUVELITY Prescription Surge After Alzheimer’s Agitation Launchmarketbeat.com
Axsome Therapeutics (NASDAQ:AXSM) executives said growth in new prescriptions for AUVELITY and an expanded sales team are positioning the company for further growth following the drug’s launch for Alzheimer’s disease agitation. Speaking at the UBS Biopharma Conference in London, Chief Financial Off
Via MarketBeat · November 16, 2026
BioMarin Pharmaceutical Sees $2.6 Billion Sales Potential in Amicus Drugs as VOXZOGO Expansion Loomsmarketbeat.com
BioMarin Pharmaceutical (NASDAQ:BMRN) expects growth from its acquired rare disease treatments, an expanded market for VOXZOGO and a pipeline that could deliver patient data in 2027, Chief Executive Officer Alexander Hardy said at the UBS Global Biopharma Conference. Hardy said the company’s global
Via MarketBeat · November 16, 2026
Vertex Pharmaceuticals Prepares for Key Kidney Drug Decision as Pipeline Readouts Loommarketbeat.com
Vertex Pharmaceuticals (NASDAQ:VRTX) is preparing for a Nov. 30 U.S. regulatory decision on its kidney disease treatment povetacicept, while awaiting clinical results across kidney disease, chronic pain and other conditions, company executives said at a UBS investor event. Susie Lisa, Vertex’s seni
Via MarketBeat · November 16, 2026
Natera CFO Maps Multiple Paths to $6 Billion Revenue Target by 2029marketbeat.com
Natera (NASDAQ:NTRA) Chief Financial Officer Mike Brophy said the company has multiple paths to its $6 billion revenue target for 2029, citing growth in its Signatera cancer testing business and opportunities to improve reimbursement. Speaking at a UBS event, Brophy also addressed Natera’s CEO tran
Via MarketBeat · November 15, 2026
Butterfly Network CEO Sees Chip Revenue Dwarfing Ultrasound Device Businessmarketbeat.com
Butterfly Network (NYSE:BFLY) is expanding beyond its handheld point-of-care ultrasound business by licensing its semiconductor technology to other companies, CEO Joe DeVivo said during a discussion with UBS MedTech team member Patrick Wood. DeVivo said the company continues to sell ultrasound devi
Via MarketBeat · November 13, 2026
Elevance Health Targets 12% Earnings Growth in 2027 as Insurance Margins Recovermarketbeat.com
Elevance Health (NYSE:ELV) expects adjusted earnings per share to grow at least 12% in 2027 from its recently increased 2026 baseline of at least $26.75, Chief Financial Officer Mark Kaye said at a UBS conference. Kaye said the outlook rests on improving health insurance margins, disciplined pricin
Via MarketBeat · November 13, 2026
Schrodinger Eyes Growth From AI Assistant Bunsen and Hosted Software Shiftmarketbeat.com
Schrodinger (NASDAQ:SDGR) is looking to its artificial intelligence assistant Bunsen and a shift toward hosted software contracts to expand use of its molecular discovery platform, executives said at the UBS Global Healthcare Conference. Chief Financial Officer Richie Jain said the company expects
Via MarketBeat · November 13, 2026
Shoulder Innovations Doubles Customer Growth, Sets Sights on Surgical Roboticsmarketbeat.com
Shoulder Innovations (NYSE:SI) is targeting high-volume shoulder surgeons with its implant system and planning technology while developing a portable surgical robot and considering expansion into soft-tissue procedures, CEO Rob Ball said during a discussion with UBS MedTech’s Patrick Wood. Ball sai
Via MarketBeat · November 13, 2026
Labcorp’s Lab Growth Surges as $125 Million Reimbursement Risk Loomsmarketbeat.com
Labcorp (NYSE:LH) Chief Financial Officer Julia Wang said strength in the company’s central laboratory business and diagnostic testing helped drive third-quarter growth, while management prepares for a potential reduction in government reimbursement rates in 2027. Speaking at the UBS Global Healthc
Via MarketBeat · November 13, 2026
UBS Thinks Rivian Stock Can Hit $17. Is It a Buy?fool.com
Record growth, a potential turnaround, and a major financial challenge are pulling this EV stock in opposite directions. Here's what could determine where it goes next.
Via The Motley Fool · November 13, 2026
This ETF Has Gained 23% This Year. Is It Still Worth Buying in 2026?fool.com
Defensive sectors are making a comeback in 2026. This one seems particularly well-positioned for 2027.
Via The Motley Fool · November 13, 2026
Rivian Just Earned a Buy Rating. Is Wall Street Seeing a Turning Point?fool.com
Rivian just received an upgrade from Wall Street, but the reasoning behind the upgrade is important.
Via The Motley Fool · November 12, 2026
Why Advanced Micro Devices Stock Popped Todayfool.com
It's more than just CoreWeave's earnings beat that's lifting AMD stock today.
Via The Motley Fool · November 11, 2026
Prediction: This Will Be Nvidia’s Stock Price By the End of 2027fool.com
Nvidia has been in the news for the wrong reason lately, but investors shouldn't overlook the company's strong prospects and cheap valuation.
Via The Motley Fool · November 11, 2026
Lloyds Banking Group Sees Slower 2027 Interest Income Growth as Competition Bitesmarketbeat.com
Lloyds Banking Group (NYSE:LYG) expects net interest income to grow at a mid-single-digit pace in 2027, slowing from this year as competition for loans and deposits continues, Chief Financial Officer William Chalmers said at the UBS European Conference. Chalmers said the bank remains confident in m
Via MarketBeat · November 11, 2026
Illumina Bets on Clinical Demand for Growth as Research Funding Uncertainty Persistsmarketbeat.com
Illumina (NASDAQ:ILMN) expects clinical demand and sequencing consumables to remain central to its growth strategy, even as research customers continue to face uncertainty over grant funding, executives said at a UBS discussion. CEO Jacob Thaysen said the company remains on the trajectory outlined
Via MarketBeat · November 10, 2026
UBS: 3 Key Takeaways for Long-Term Investorsfool.com
Proposed Swiss capital rules could constrain the bank's global expansion, even as integration progress unlocks shareholder returns.
Via The Motley Fool · November 9, 2026
Danaher CEO Sees Faster Growth Ahead, With AI and Acquisitions in Focusmarketbeat.com
Danaher (NYSE:DHR) President and CEO Julie Sawyer Montgomery said the company is aiming for faster core growth and market share gains through stronger commercial execution, innovation and acquisitions, as it pursues a leadership position in life sciences and diagnostics. Speaking at a UBS conferenc
Via MarketBeat · November 9, 2026
This Prediction-Markets Bet Ignites Worry On Wall Streetinvestors.com
JPMorgan Chase, UBS and Stifel downgraded DraftKings after it cut its outlook. The stock is trading at its lowest level since April 2023.
Via Investor's Business Daily · November 9, 2026